Vaccine
Cure8 research brief
Why This Matters
Patients with IBD—particularly those on anti‑TNF therapy and older adults—may have lower and faster‑waning antibody responses after mRNA COVID‑19 vaccination, which could affect timing or need for additional vaccine doses or monitoring strategies.
The study suggests cellular immune responses were relatively preserved despite differences in humoral responses.
Who Should Pay Attention
Adults with IBD (especially on anti‑TNF biologics), clinicians managing IBD and vaccination, and researchers studying vaccine immunogenicity.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This prospective cohort study followed adults with IBD for 12 months after SARS-CoV-2 mRNA vaccination, measuring antibody (S1-RBD IgG) levels, live-virus neutralisation titres against several variants, and IFN-γ ELISpot cellular responses at baseline, 3, 6 and 12 months.
All infection‑naive patients seroconverted by 3 months, but antibody levels and neutralisation declined by 6 months, especially in patients receiving anti-TNF therapy and with increasing age.
A third vaccine dose and intercurrent infection raised antibody levels, with infection producing a larger fold-rise than the third dose alone; cellular (IFN-γ) responses did not differ by treatment group in adjusted analyses. The study reports laboratory immune measures rather than clinical outcomes.
It is exploratory and relatively small (53 twice-vaccinated, 33 thrice-vaccinated patients), and the authors state the associations need confirmation in larger cohorts with clinical endpoints.
Keep In Mind
Findings are from a single‑centre prospective cohort with laboratory immunologic endpoints; clinical protection against infection or severe disease was not assessed. Results are exploratory and need confirmation in larger cohorts.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationVaccine
AuthorsWolfram Mayr, Astrid I Knell, Anna K Boehm +8 more
InstitutionDepartment of Internal Medicine II, Infectious Diseases, Immunology, Rheumatology, Pneumology, Medical University of Innsbruck, Innsbruck, Austria.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 8, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Immunogenicity of an additional COVID-19 mRNA vaccine dose in immunosuppressed children with two doses of primary immunization.
An extra mRNA COVID-19 vaccine dose produced only modest increases in antibody and T‑cell responses in immunosuppressed children (including those with IBD), so vaccine protection may still be lower than in healthy...
Circulating SARS-CoV-2 Spike IgG Antibody Levels and Avidity in Autoimmune, IBD and Transplant Cohorts: An Observational Study Following Multiple COVID-19 Vaccine Boosters.
People with IBD and other immune conditions may develop weaker or lower‑quality antibody responses after COVID‑19 vaccination compared with healthy people, and transplant recipients showed the largest impairments. That...
Computed tomography enterography-defined transmural healing is associated with lower hospitalization risk in patients with Crohn's disease.
Transmural healing on CT enterography was associated with fewer hospitalizations over long follow-up, which could matter for long-term disease management and monitoring strategies in Crohn’s disease.